Boy with delayed Fabry disease diagnosis improves with ERT

Tests found no evidence of organ damage despite 10-year delay

Written by Margarida Maia, PhD |

A doctor holding a clipboard speaks to a child, with both subjects' faces not pictured.

A report describes the case of an adolescent boy in Morocco who, despite a 10-year diagnostic delay, was diagnosed with Fabry disease prior to any organ involvement.

Timely diagnosis is important for identifying Fabry disease in children and starting treatment before irreversible organ damage occurs, as illustrated by the case of an adolescent boy who, despite a 10-year diagnostic delay, was diagnosed prior to any organ involvement.

After starting Fabrazyme (agalsidase beta), the boy experienced less severe neuropathic (nerve) pain and was better able to tolerate exercise.

Newborn screening can identify Fabry before symptoms appear, but the disease is not screened at birth in Morocco, where the boy lived.

“Early recognition in childhood is critical to optimize outcomes and modify disease,” researchers wrote in “Pediatric Fabry disease revealed by early neuropathic symptoms: a case report,” which was published in Oxford Medical Case Reports.

Recommended Reading
One clinician holds a gigantic magnifying glass in front of a patient as another takes notes on a clipboard.

Fabry therapy switch linked to less pain, lower biomarker in boy

Recognizing the disease early is crucial

In Fabry, disease-causing mutations result in a lack of functional alpha-galactosidase A (alpha-Gal A), an enzyme that breaks down fatty molecules inside cells. Without this enzyme, fatty molecules can build up to toxic levels and damage organs. The classic form of Fabry begins in childhood or adolescence, but early symptoms may be overlooked because they can mimic other diseases.

Recognizing the disease early is important because treatment can slow its progression and reduce the risk of permanent organ damage.

“This case illustrates that prompt biochemical and genetic evaluation in patients with unexplained neuropathic symptoms enables early treatment initiation,” the researchers wrote.

The case involved a 14-year-old boy who had experienced symptoms since age 4. He reported burning pain or tingling in the hands and feet, along with abdominal pain, tiredness, and difficulty exercising. He also had anhidrosis, meaning that he could not sweat normally. These symptoms can occur when Fabry affects nerves and the body’s ability to regulate temperature.

A physical examination showed that the boy was shorter than expected for his age and had reduced sensitivity to pinprick and vibration in his lower legs. These findings suggested peripheral neuropathy, which occurs when nerves branching off the brain and spinal cord are damaged.

ERT can slow disease progression, particularly when initiated before irreversible organ damage occurs.

Blood tests showed that his alpha-Gal A was almost absent, while lyso-Gb3, a fatty substance that builds up when the enzyme does not function properly, was very high. These results strongly suggested Fabry. Genetic testing confirmed the diagnosis by identifying a disease-causing mutation in the GLA gene, which codes for the alpha-Gal A enzyme.

The boy had a hemizygous nonsense mutation, meaning his single copy of this gene on the X chromosome carried the mutation. The mutation, called c.658C>T (p.Arg220*), inserts an early stop signal that prevents the body from producing a fully functional enzyme. Genetic screening identified the same mutation in his mother and a maternal uncle, who also showed symptoms.

Further tests found no evidence of damage to his kidneys, heart, eyes, or blood vessels in the brain, although he had experienced symptoms for about 10 years.

“Our patient exhibited characteristic early symptoms but experienced a significant diagnostic delay,” the researchers wrote. “Careful family history and biochemical testing can facilitate timely diagnosis and intervention.”

Doctors started enzyme replacement therapy (ERT) with Fabrazyme, which is approved to treat adults and children ages 2 and older with Fabry. This treatment supplies a functional version of the missing enzyme, helping cells break down the accumulated fatty substances. The boy tolerated treatment well and reported less severe nerve pain and an improved ability to exercise.

“ERT can slow disease progression, particularly when initiated before irreversible organ damage occurs,” the researchers wrote. “This case underscores the importance of recognizing neuropathic pain and heat intolerance in children as potential early signs of [Fabry disease],” they concluded.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.